Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease

P. E. Bendheim, B. Poeggeler, E. Neria, V. Ziv, M. A. Pappolla, D. G. Chain

Research output: Contribution to journalArticlepeer-review

131 Scopus citations


The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON™) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)213-217
Number of pages5
JournalJournal of Molecular Neuroscience
Issue number1-2
StatePublished - 2002
Externally publishedYes


  • Alzheimer's disease
  • Beta-amyloid
  • Indole-3-propionic acid
  • Oxidative stress

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this